[go: up one dir, main page]

TN2015000099A1 - Methods for treatment of alport syndrome - Google Patents

Methods for treatment of alport syndrome

Info

Publication number
TN2015000099A1
TN2015000099A1 TNP2015000099A TN2015000099A TN2015000099A1 TN 2015000099 A1 TN2015000099 A1 TN 2015000099A1 TN P2015000099 A TNP2015000099 A TN P2015000099A TN 2015000099 A TN2015000099 A TN 2015000099A TN 2015000099 A1 TN2015000099 A1 TN 2015000099A1
Authority
TN
Tunisia
Prior art keywords
alport syndrome
mir
treatment
methods
certain embodiments
Prior art date
Application number
TNP2015000099A
Other languages
English (en)
Inventor
Jeremy Duffield
Balkrishen Bhat
Deidre Mackenna
Original Assignee
Regulus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regulus Therapeutics Inc filed Critical Regulus Therapeutics Inc
Publication of TN2015000099A1 publication Critical patent/TN2015000099A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/313—Phosphorodithioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
TNP2015000099A 2012-10-09 2015-03-16 Methods for treatment of alport syndrome TN2015000099A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261711514P 2012-10-09 2012-10-09
US201361779137P 2013-03-13 2013-03-13
PCT/US2013/063884 WO2014058881A1 (fr) 2012-10-09 2013-10-08 Méthodes de traitement du syndrome d'alport

Publications (1)

Publication Number Publication Date
TN2015000099A1 true TN2015000099A1 (en) 2016-06-29

Family

ID=49382663

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2015000099A TN2015000099A1 (en) 2012-10-09 2015-03-16 Methods for treatment of alport syndrome

Country Status (34)

Country Link
US (8) US9012423B2 (fr)
EP (2) EP2906698B1 (fr)
JP (4) JP6272880B2 (fr)
KR (4) KR20230136686A (fr)
CN (1) CN104718295B (fr)
AR (1) AR092940A1 (fr)
AU (3) AU2013329427B2 (fr)
BR (1) BR112015007709B1 (fr)
CA (1) CA2885605A1 (fr)
CL (1) CL2015000873A1 (fr)
CR (1) CR20150236A (fr)
CY (1) CY1122479T1 (fr)
DK (1) DK2906698T3 (fr)
EA (1) EA201590711A1 (fr)
ES (2) ES2960488T3 (fr)
HR (1) HRP20191948T1 (fr)
HU (1) HUE045858T2 (fr)
IL (2) IL237768B (fr)
LT (1) LT2906698T (fr)
MX (1) MX356340B (fr)
MY (1) MY183921A (fr)
NZ (1) NZ630596A (fr)
PH (1) PH12015500781B1 (fr)
PL (1) PL2906698T3 (fr)
PT (1) PT2906698T (fr)
RS (1) RS60014B1 (fr)
SG (1) SG11201502748RA (fr)
SI (1) SI2906698T1 (fr)
TN (1) TN2015000099A1 (fr)
TW (1) TWI641388B (fr)
UA (1) UA116639C2 (fr)
UY (1) UY35069A (fr)
WO (1) WO2014058881A1 (fr)
ZA (1) ZA201502087B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2857881A1 (fr) 2004-11-12 2006-12-28 Asuragen, Inc. Procedes et compositions comprenant des molecules de micro-arn et des molecules d'inhibiteur de micro-arn
DK2702155T3 (en) 2011-04-25 2017-05-01 Regulus Therapeutics Inc MICRO-RNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY
NZ630591A (en) 2012-04-25 2017-02-24 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-21 activity
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
US9994846B2 (en) 2013-10-25 2018-06-12 Regulus Therapeutics Inc. MicroRNA compounds and methods for modulating miR-21 activity
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
EP3171889A4 (fr) * 2014-07-25 2018-03-14 Goldfinch Biopharma, Inc. Remplacement de collagène iv
CA2958585C (fr) 2014-08-21 2024-01-09 Stealth Biotherapeutics Corp Utilisation de peptide d-arg-2',6'-dmt-lys-phe-nh2 pour le traitement du syndrome d'alport
CN107109411B (zh) 2014-10-03 2022-07-01 冷泉港实验室 核基因输出的定向增加
EP3359685A1 (fr) 2015-10-09 2018-08-15 University Of Southampton Modulation de l'expression génique et criblage de l'expression de protéines dérégulée
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
US11083745B2 (en) 2015-12-14 2021-08-10 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet Syndrome
US10953020B2 (en) 2016-11-08 2021-03-23 Reata Pharmaceuticals, Inc. Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
JP7072748B2 (ja) 2016-12-28 2022-05-23 国立大学法人神戸大学 アルポート症候群治療薬
CN116585344A (zh) * 2017-05-04 2023-08-15 赛诺菲 用于治疗奥尔波特综合征的方法
WO2018226900A2 (fr) 2017-06-06 2018-12-13 Zymergen Inc. Plate-forme d'ingénierie génomique htp permettant d'améliorer les souches fongiques
EP3878961A1 (fr) 2017-06-06 2021-09-15 Zymergen, Inc. Plate-forme d'ingénierie génomique htp permettant d'améliorer escherichia coli
SMT202400071T1 (it) 2017-08-25 2024-03-13 Stoke Therapeutics Inc Oligomeri antisenso per il trattamento di condizioni e malattie
HRP20250322T1 (hr) 2017-10-23 2025-06-06 Stoke Therapeutics, Inc. Protusmisleni oligomeri, namijenjeni liječenju stanja i bolesti uzrokovanih raspadanjem rna posredovanim besmislenim mutacijama
JP2021523227A (ja) 2018-05-04 2021-09-02 ストーク セラピューティクス，インク． コレステリルエステル蓄積症の処置のための方法及び組成物
WO2020092704A1 (fr) 2018-10-31 2020-05-07 Zymergen Inc. Ensemble déterministe multiplexé de bibliothèques d'adn
US11053515B2 (en) 2019-03-08 2021-07-06 Zymergen Inc. Pooled genome editing in microbes
JP2022524043A (ja) 2019-03-08 2022-04-27 ザイマージェン インコーポレイテッド 微生物の反復ゲノム編集
WO2021189010A1 (fr) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Procédés d'utilisation de variants de récepteur de l'activine de type iib
CA3173647A1 (fr) 2020-05-11 2021-11-18 Isabel AZNAREZ Oligomeres antisens opa1 pour le traitement de pathologies et de maladies
WO2023217764A1 (fr) * 2022-05-09 2023-11-16 Calliditas Therapeutics Suisse Sa Inhibiteurs de nox destinés à être utilisés dans le traitement du syndrome d'alport
WO2024238950A1 (fr) * 2023-05-18 2024-11-21 Keros Therapeutics, Inc. Procédés d'utilisation de variants du récepteur de l'activine de type ii
WO2025110217A1 (fr) * 2023-11-22 2025-05-30 国立大学法人東海国立大学機構 Agent prophylactique et/ou thérapeutique pour maladies kystiques rénales

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1038886B (zh) * 1998-05-22 2005-09-23 博伊斯镇国家研究医院 α1β1整合蛋白受体抑制剂和TGF-β1抑制剂制备用於治疗肾病的药物组合物的用途
CZ296262B6 (cs) 1998-05-22 2006-02-15 Boys Town National Research Hospital Farmaceutický prostredek
US20060008817A1 (en) 2000-12-08 2006-01-12 Invitrogen Corporation Methods and compositions for generating recombinant nucleic acid molecules
IL161100A0 (en) 2001-09-28 2004-08-31 Max Planck Gesellschaft Identification of novel genes coding for small temporal rnas
US7585501B2 (en) * 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
EP1648914A4 (fr) 2003-07-31 2009-12-16 Regulus Therapeutics Inc Composes oligomeres et compositions utilisables pour moduler des petits arn non-codants
ITMI20032528A1 (it) * 2003-12-19 2005-06-20 Francesco Santangelo Uso di cistina o di cisteina per la prevenzione e il
US7585550B2 (en) 2004-02-02 2009-09-08 College Of William And Mary Process for modifying polymeric surfaces using deep UV irradiation
AU2005250432B2 (en) 2004-05-28 2011-09-15 Asuragen, Inc. Methods and compositions involving microRNA
WO2006020768A2 (fr) 2004-08-10 2006-02-23 Alnylam Pharmaceuticals, Inc. Oligonucleotides chimiquement modifies
JP2008512463A (ja) * 2004-09-08 2008-04-24 ボーイズ タウン ナショナル リサーチ ホスピタル マトリックスメタロプロテイナーゼ−１２に関連する糸球体基底膜疾患の治療
CA2857881A1 (fr) 2004-11-12 2006-12-28 Asuragen, Inc. Procedes et compositions comprenant des molecules de micro-arn et des molecules d'inhibiteur de micro-arn
EP1959012A3 (fr) 2004-12-29 2009-12-30 Exiqon A/S Nouvelles compositions oligonucléotides et séquences de sonde utiles pour la détection et l'analyse de micro ARN et leurs ARN cibles
US6995235B1 (en) 2005-05-02 2006-02-07 Univation Technologies, Llc Methods of producing polyolefins and films therefrom
DK1931780T3 (en) * 2005-08-29 2016-01-25 Regulus Therapeutics Inc Antisense-forbindelser med forøget anti-microrna-aktivitet
JP5213723B2 (ja) 2006-01-27 2013-06-19 アイシス ファーマシューティカルズ， インコーポレーテッド マイクロｒｎａの調節に使用するためのオリゴマー化合物及び組成物
ES2569558T3 (es) 2006-04-03 2016-05-11 Roche Innovation Center Copenhagen A/S Composición farmacéutica que comprende oligonucleótidos antisentido anti-ARNmi
MX2008012219A (es) 2006-04-03 2008-10-02 Santaris Pharma As Composicion farmaceutica que comprende oligonucleotidos antisentido anti-miarn.
WO2008042973A2 (fr) 2006-10-03 2008-04-10 Alnylam Pharmaceuticals, Inc. Formulations contenant un lipide
US8906870B2 (en) 2006-10-09 2014-12-09 Julius-Maximilians-Universitaet Wuerzberg MicroRNA (miRNA) for the diagnosis and treatment of heart diseases
WO2008073920A2 (fr) 2006-12-08 2008-06-19 Asuragen, Inc. Gènes et voies génétiques régulés par mir-21 utilisés en tant que cibles pour une intervention thérapeutique
EP2118118B1 (fr) 2007-01-19 2017-09-27 Exiqon A/S Apport cellulaire médié d'oligonucléotides de lna
WO2008151631A2 (fr) 2007-06-15 2008-12-18 Exiqon A/S Utilisation de courts oligonucléotides pour des expériences à redondance de réactif dans une analyse fonctionnelle d'arn
CA2691691C (fr) * 2007-06-20 2013-09-24 Seth J. Baum Compositions et procedes pour traiter la maladie chronique des reins
AU2008306327B2 (en) 2007-10-04 2014-05-15 Roche Innovation Center Copenhagen A/S Micromirs
JP5535076B2 (ja) 2007-10-29 2014-07-02 レグルス・セラピューティクス・インコーポレイテッド 肝臓癌を治療するための標的化ミクロｒｎａ
WO2009091972A2 (fr) 2008-01-18 2009-07-23 Alnylam Pharmaceuticals, Inc. Oligonucléotides modifiés chimiquement et petites molécules à utiliser dans la réduction des taux d'activité de microarn et leurs utilisations
JP2011510678A (ja) * 2008-02-08 2011-04-07 プロセンサ ホールディング ビーブイ Ｄｎａ反復不安定性関連遺伝性障害を治療するための方法及び手段
EP2096171A1 (fr) 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg Cibles microARN (miARN) et en aval à des fins de diagnostic et thérapeutiques
US8404659B2 (en) 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
CA2753562A1 (fr) 2009-02-26 2010-09-02 The Ohio State University Research Foundation Microarn chez les non-fumeurs et methodes et matieres apparentees
US20120148664A1 (en) 2009-06-08 2012-06-14 Miragen Therapeutics Chemical modifications motifs for mirna inhibitors and mimetics
WO2011126842A2 (fr) 2010-03-30 2011-10-13 Regulus Therapeutics Inc. Ciblage de micro-arn pour le traitement de troubles cardiaques
DK2702155T3 (en) 2011-04-25 2017-05-01 Regulus Therapeutics Inc MICRO-RNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY
WO2013013165A2 (fr) 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Utilisation de composés d'acide nucléique bloqué (lna) pour l'inhibition thérapeutique de mir-21 dans le lupus érythémateux systémique
NZ630591A (en) 2012-04-25 2017-02-24 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-21 activity
CN104685056A (zh) 2012-06-21 2015-06-03 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
CA2886116C (fr) 2012-09-26 2022-06-07 Mirrx Therapeutics Oligomeres a profil hors cible ameliore
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта

Also Published As

Publication number Publication date
JP2020073479A (ja) 2020-05-14
MY183921A (en) 2021-03-17
IL237768B (en) 2018-10-31
EA201590711A1 (ru) 2015-07-30
CN104718295A (zh) 2015-06-17
US20200283765A1 (en) 2020-09-10
PL2906698T3 (pl) 2020-05-18
KR20200118245A (ko) 2020-10-14
ES2960488T3 (es) 2024-03-05
WO2014058881A1 (fr) 2014-04-17
PH12015500781A1 (en) 2015-06-15
US9688986B2 (en) 2017-06-27
KR20230136686A (ko) 2023-09-26
JP2015536301A (ja) 2015-12-21
US9012423B2 (en) 2015-04-21
ES2753174T3 (es) 2020-04-07
AU2019210494A1 (en) 2019-08-15
US20140100263A1 (en) 2014-04-10
EP2906698B1 (fr) 2019-07-31
CL2015000873A1 (es) 2015-08-14
BR112015007709B1 (pt) 2022-05-17
US20170369879A1 (en) 2017-12-28
US20160319283A1 (en) 2016-11-03
KR102165189B1 (ko) 2020-10-14
US20220098582A1 (en) 2022-03-31
HRP20191948T1 (hr) 2020-04-03
UA116639C2 (uk) 2018-04-25
US20150299704A1 (en) 2015-10-22
EP2906698A1 (fr) 2015-08-19
AU2021269404A1 (en) 2021-12-16
BR112015007709A2 (pt) 2017-08-08
KR102349184B1 (ko) 2022-01-07
TW201420120A (zh) 2014-06-01
PT2906698T (pt) 2019-11-05
JP2018080190A (ja) 2018-05-24
SG11201502748RA (en) 2015-05-28
MX2015004460A (es) 2015-11-23
RS60014B1 (sr) 2020-04-30
JP6272880B2 (ja) 2018-01-31
US9359609B2 (en) 2016-06-07
CR20150236A (es) 2015-06-30
UY35069A (es) 2014-04-30
NZ630596A (en) 2017-05-26
JP2022110140A (ja) 2022-07-28
KR20220005634A (ko) 2022-01-13
DK2906698T3 (da) 2019-11-04
MX356340B (es) 2018-05-23
EP3620522A1 (fr) 2020-03-11
US20180298385A1 (en) 2018-10-18
PH12015500781B1 (en) 2015-06-15
KR20150064072A (ko) 2015-06-10
SI2906698T1 (sl) 2019-11-29
ZA201502087B (en) 2016-06-29
US9970011B2 (en) 2018-05-15
EP3620522B1 (fr) 2023-07-26
TWI641388B (zh) 2018-11-21
CA2885605A1 (fr) 2014-04-17
AU2013329427A1 (en) 2015-04-02
CY1122479T1 (el) 2021-01-27
HUE045858T2 (hu) 2020-01-28
AR092940A1 (es) 2015-05-06
HK1212378A1 (en) 2016-06-10
US20240167032A1 (en) 2024-05-23
LT2906698T (lt) 2019-11-11
IL262200A (en) 2018-11-29
CN104718295B (zh) 2020-03-13
AU2013329427B2 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
PH12015500781A1 (en) Methods for treatment of alport syndrome
PH12013501636A1 (en) Treatment of osteoarthritis and pain
CL2013003341A1 (es) Un metodo y sistema para autenticar una sesion de un usuario.
GB201502755D0 (en) Supported catalyst and active form thereof, and preparation method and use
EA201391585A1 (ru) Терапевтические нуклеазные композиции и способы
BRPI1010718A2 (pt) sistemas modelo e regimes de tratamento para tratar doença neurológica.
WO2009129387A3 (fr) Lipides cationiques et utilisations associees
CA147873S (en) Teapot
MX2018007307A (es) Conjugados de peptidos y oligonucleotidos.
MX347620B (es) Derivados de sulfonilaminopirrolidinona, su preparacion y aplicacion terapeutica.
MX2019013158A (es) Metodos para el tratamiento del sindrome de alport.
AR128192A2 (es) Métodos para el tratamiento del síndrome de alport
AR119688A2 (es) Métodos para el tratamiento del síndrome de alport
MX2013012551A (es) Uso de sales de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio en el tratamiento de enfermedades cardiovasculares.
WO2012120438A3 (fr) Systèmes et procédés destinés à être utilisés dans la conception de médicaments moléculaires
卢希 Creek Maze
陈征宇 Understanding DNA chains in confinement by using the wormlike-chain model
Fu Winner Takes All: A Belligerent Male Society——Discourse Strategies in Glengarry Glen Ross
周游 What can you do?
童国梁 DESY/CERN
PAVAN The Italian Market of Business Angels: Determinants of Performance
Шапошникова The organization of social work within the framework of socialization of modern youth
高虹 Mansfield's New Zealand Identity in Her Short Stories
唐宇 Happy New Year!
李文良 et al. 甘肃天水宽沟金矿床同位素地球化学特征研究